BackgroundTwitter® (www.twitter.com) has become a useful digital tool for professional networking, update of knowledge and communication in the Spanish hospital pharmacy community.It is estimated that the number of Spanish Hospital pharmacists (SHP) is approximately 3,500, but the rate of SHP using Twitter is not well known.PurposeTo estimate what percentage of SHP have an active Twitter account.Material and methodsA cross-sectional descriptive study was carried out from 26 September 2017 to 14 October 2017.A new Twitter profile was created in privacy mode on the Google Chrome browser.SHP profiles were identified through the ‘snowball’ method following a four-steps procedure:Searching by keywords and hashtag on Twitter: ‘#FarmaciaHospitalaria’ + ‘Farmacia Hospitalaria’ + ‘Farmacéutica de Hospital’ + ‘Farmacéutico de Hospital’ + ‘Farmacia de Hospital’ + ‘Farmacéutica especialista’ + ‘Farmacéutico especialista’+ ‘Farmacia Hospital’ + ‘Hospital Pharmacist’ + ‘Hospital Pharmacy’ + ‘FIR’ and ‘#FIR’.Finding twitter lists related to ‘Farmacia Hospitalaria’ after searching on Google ‘inurl:lists inurl:Farmacia Hospitalaria site:twitter. com’.Followers and lists of Spanish Society of Hospital Pharmacist (@sefh_).Using ‘Who to follow’ functionality on Twitter.Inclusion criteria were:Twitter accounts self–identified as HP or HP resident or shown as prespecified keywords in their biography.The exclusion criteria were:Non–institutional or personal profiles related with hospital pharmacy.Private companies profiles.Profiles without photo.Non–Spanish accounts.Each Twitter profile that met the inclusion criteria was followed by the new created account.To export the following accounts database and to analyse the data, two online tools were used: Twittonomy and Google Sheets, respectively.ResultsA total of 698 Twitter accounts were identified as SHP. Most of them (64.2%, n=448) corresponded with feminine profiles, and the rest were masculine (26.5%, n=185) or non-determined (9.3%, n=65).The number of institutional profiles was 22 (five associated with theSpanish Society of Hospital Pharmacy and 17 associated with their work teams).At the time of the study 25 Spanish Hospital Pharmacy Departments have an active Twitter profile.The rate of SHP with a Twitter account was 18.1%.ConclusionThere are many institutional Twitter accounts associated with the Spanish Society of Hospital Pharmacy.Despite being a relevant hospital pharmacist community, the rate of SHP with a presence on Twitter is still low.References and/or AcknowledgementsSociedad Española de Farmacia Hospitalaria (SEFH). SEFH, como organizarnos. Jornadas ‘EL POTENCIAL DE la SEFH’, puesta al día (07/06/2017) https://www. sefh. es/sefhjornadas/48_Sefh_como_organizarnos. pdfNo conflict of interest

BackgroundThe number of medical apps has increased exponentially in recent years, with more than 2 30 000 available.Because of the lack of regulation, some of these apps may offer inaccurate content or may not reach the minimum quality standards in order to be used by healthcare professionals.PurposeAnalyse the availability of drug interaction checker apps for mobile devices and their quality according to the Mobile App Rating Scale (MARS score).Material and methodsCross-sectional study performed in October 2017 to find and classify the best mobile applications to check drug interactions according to MARS score.A search was conducted on two major mobile platforms: Apple’s App Store and Google Play Store. The keyword used to identify the initial sample was ‘drug interaction’.The exclusion criteria were:No drug searcher available or drug searcher only available for a specific drug class.No health and fitness or medicine category.No English language.Pay subscription app.Not updated in the last 36 months.The selected apps were downloaded in a smartphone and in a tablet of both systems in order to be analysed. The app’s quality and reliability was measured by means of MARS. This is an app quality rating tool that provides a measure of different features of health apps. It consists of 19 items clustered in four categories: engagement, functionality, aesthetics and information. Each item is rated in a 1–5 points scale (1-inadequate to 5-excellent).The degree of agreement between the selected apps was not analysed.Data collection and statistical analysis were performed in a Google Drive spreadsheet.ResultsOf the 139 apps identified, 12 met the inclusion and exclusion criteria. The mean MARS score was 3.01 (1.93–4.28). The mean social score was 4.03. The five apps with best MARS score (0–5) were ‘Medscape’ (4. 28), ‘Drugs.com Medication Guide’ (4.08), ‘Pharmacist Pro-Drug Interaction Checker’ (3.61), ‘Pocket Pharmacist’ (3.55) and ‘Assist UK-Drug Interactions’ (3.26).ConclusionThere is a high amount of apps to check drug interactions but only few have enough quality to be used with guarantees by healthcare professionals in their clinical activity.Reference and/or Acknowledgements1. Stoyanov SR, et al. Mobile app rating scale: a new tool for assessing the quality of health mobile apps. JMIR mHealth and uHealth2015.No conflict of interest

No abstract

The compounded product has suitable pharmaceutical characteristics, such as rheology, in vitro release profile and a pH value suitable for oral administration.Its clinical application in a patient with grade 3 mucositis resulted in excellent acceptability and significant reduction in the degree of mucositis (for grade I) and re-introduction of EVR into the therapeutic regimen at the end of a week of treatment with the gel. Conclusion This mucoadhesive gel can be an effective option for the prophylaxis/treatment of oral mucositis, for its prolonged residence time in the oral cavity and easier administration. The pleasant taste promotes a good therapeutic compliance, as well as the smooth and suitable texture for the treatment of an aggressive mucosa. The inclusion of more patients in this study will validate these assumptions. REFERENCE AND/OR ACKNOWLEDGEMENTSRugo HS, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol [Internet]